연구동향 분석
박사

약물 방출 관상동맥 스텐트 시술 후 스텐트 혈전증 발생 환자의 임상경과

김인수 2015년

논문상세정보
인용/피인용
' 약물 방출 관상동맥 스텐트 시술 후 스텐트 혈전증 발생 환자의 임상경과' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 스텐트 혈전증
  • 약물 용출 스텐트
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
18 2

0.0%

' 약물 방출 관상동맥 스텐트 시술 후 스텐트 혈전증 발생 환자의 임상경과' 의 참고문헌

  • van der Hoeven BL, Liem SS, Jukema JW, et al., Sirolimus-ElutingStents versus Bare-Metal Stents in Patients with ST-SegmentElevation Myocardial Infarction: 9-Month Angiographic andIntravascular Ultrasound Results and 12-Month Clinical OutcomeResults from the MISSION! Intervention Study, J Am Coll CardiolVol.51,pp.618-26,2008.
  • Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T,Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. LocalizedHypersensitivity and Late Coronary Thrombosis Secondary to aSirolimus-ElutingStent.Circulation,Vol.109,pp.701-5,2004.
  • Virmani R, Farb A, Guagliumi G, Kolodgie FD. Drug-ElutingStents:CautionandConcernsforLong-TermOutcome.CoronArteryDis,Vol.15,pp.313-8,2004.
  • The Korean Society of Medical Imaging Technology, "Textbook ofVascularandInterventionalRadiography",Chung-KuPub.,2009.
  • SudhirK,HermillerJB,FergusonJM,SimontonCA,RiskFactorsforCoronary Drug-Eluting Stent Thrombosis: Influence of Procedural,Patient, Lesion, and Stent Related Factors and Dual AntiplateletTherapy.ISRNCardiol,pp.748-36,2013.
  • StoneGW,MosesJW,EllisSG,SchoferJ,DawkinsKD,MoriceMC,etal., Safety and Efficacy of Sirolimus-and Paclitaxel-ElutingCoronaryStents.NEnglJMed,VOl.356,pp.998-1008,2007.
  • Stefanini GG, Kalesan B, Serruys PW, Heg D, Buszman P, Linke A,Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C,Corti R, Antoni D, Sohn HY, Eerdmans P, van Es GA, Meier B,Windecker S, Juni P, Long-Term Clinical Outcomes of BiodegradablePolymer Biolimus-Eluting Stents versus Durable Polymer Sirolimus-ElutingStentsinPatientswithCoronaryArteryDisease(LEADERS):4Year follow-up of a Randomised Non-Inferiority Trial. LancetVol.378,pp.1940-8,2011.
  • SiddiqiOK,FaxonDP,VeryLateStentThrombosis:CurrentConcepts,CurrOpinCardiol,Vol.27,pp.634-41,2012.
  • SerruysPW,vanHoutB,BonnierH,LegrandV,GarciaE,MacayaC,etal.,RandomisedComparisonofImplantationofHeparin-CoatedStentswith Balloon Angioplasty in Selected Patients with Coronary ArteryDisease(BenestentII),Lancet,Vol.352,pp.673-81.1998.
  • SalamAM,alSuwaidiJ,HolmesDRJr,etal.,Drug-elutingcoronarystents,CurrProblCardiol,Vol.31,pp.8-119,2006.
  • S. C. Ma, H. G. Kim, B. S. Park, H. G. Goo, S. J. Yu, et al.,"VascularandInterventionalRadiology",Dai-HakPub.,2008.
  • ParkKW,HwangSJ,KwonDA,OhBH,ParkYB,ChaeIH,GwonHC,ParkSJ,SeungKB,AhnT,YoonJH,JangYS,JeongMH,TahkSJ,KimHS,KoreaStentThrombosisInvestigators.CharacteristicsandPredictorsof Drug-Eluting Stent Thrombosis: Results from the Multicenter 'KoreaStentThrombosis(KoST)'registry,CircJ,VOl.75,pp.1626-32.2011.
  • Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, et al.,Frequency of and risk factors for stent thrombosis afterdrug-eluting stent implantation during long-term follow-up. Am JCardiol,Vol.98,pp.352-56,2006.
  • Ong AT, Hoye A, Aoki J, van Mieghem CA, Rodriguez Granillo GA,SonnenscheinK,etal.,Thirty-DayIncidenceandSix-MonthClinicalOutcome of Thrombotic Stent Occlusion after Bare-Metal, Sirolimus,orPaclitaxelStentImplantation,JAmCollCardiol,Vol.45,pp.947?53.2005.
  • NebekerJR,VirmaniR,BennettCL,HoffmanJM,SamoreMH,AlvarezJ, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR,Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L,Feldman MD. Hypersensitivity Cases Associated with Drug-ElutingCoronaryStents,JAmCollCardiol,Vol.47,pp.175-81.2006.
  • Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, AlvarezJ,et al., Hypersensitivity Cases associated with Drug-ElutingCoronary Stents: a Review of available Cases from the Research onAdverseDrugEventsandReports(RADAR)project,JAmCollCardiol,Vol.47,pp.175-81.2006.
  • NakazawaG,FinnAV,JonerM,etal.,DelayedArterialHealingandIncreasedLateStentThrombosisatCulpritSitesafterDrug-ElutingStentPlacementforAcuteMyocardialInfarctionPatients:anAutopsyStudy.Circulation,Vol.118,pp.1138-45,2008.
  • Mintz GS, Tinana A, Hong MK, Lee CW, Kim JJ, Fearnot NE, et al.,Impact of Preinterventional Arterial Remodeling on NeointimalHyperplasia after Implantation of (non-Polymer-Encapsulated)Paclitaxelcoated Stents: a Serial Volumetric IntravascularUltrasoundAnalysisfromtheASianPaclitaxel-ElutingStentClinicalTrial(ASPECT),Circulation,Vol.108,pp.1295-8.2003.
  • Mauri L, Hsieh WH, Massaro JM, Ho KK, Dво?Agostino R, Cutlip DE.Stent Thrombosis in Randomized Clinical Trials of Drug-ElutingStents.NEnglJMed,Vol.356,pp.1020?29,2007.
  • Leon MB, Bakhai A. Drug-Eluting Stents and Glycoprotein IIb/IIIaInhibitors:CombinationTherapyfortheFuture,AmHeartJ,Vol.146,pp.13-7,2003.
  • LasalaJM,CoxDA,DobiesD,BaranK,BachinskyWB,RogersEW,etal., Drug-Eluting Stent Thrombosis in Routine Clinical Practice:Two-Year Outcomes and Predictors from the TAXUS ARRIVE Registries,CircCardiovascInterv,Vol.2,pp.285-93,2009.
  • Kim IS, Choi NG, Han JB, Jang SJ, Jang YI, Clinical Outcome ofStentThrombosisinPatientswithAcuteMyocardialInfarction.KoreaCulture&ContentsTechnologyAssociation,Vol.12,pp.273-83,2012.
  • KastratiA,MehilliJ,PacheJ,KaiserC,ValgimigliM,KelbaekH,et al., Analysis of 14 trials comparing sirolimus-eluting stentswithbare-metalstents.NEnglJMed,Vol.356,pp.1030-39,2007.
  • JonerM,FinnAV,FarbA,MontEK,KolodgieFD,LadichE,KutysR,SkorijaK,GoldHK,VirmaniR.PathologyofDrug-ElutingStentsinHumans.JAmCollCardiol,Vol.48,pp.193-202.2006.
  • IakovouI,SchmidtT,BonizzoniE,GeL,SangiorgiGM,StankovicG,et al., Incidence, Predictors, and Outcome of Thrombosis afterSuccessful Implantation of Drug-Eluting Stents. JAMA, Vol.293,pp.2126-30,2005.
  • HolmesDRJr,LeonMB,MosesJW,PopmaJJ,CutlipD,FitzgeraldPJetal.,Analysisof1-yearClinicalOutcomesintheSIRIUSTrial:aRandomized Trial of a Sirolimus-Eluting Stent versus a StandardStentinPatientsatHighRiskforCoronaryRestenosis,CirculationVol.109,pp.634-40,2004.
  • Guo N, Maehara A, Mintz GS, et al., Incidence, Mechanisms,PredictorsandClinicalImpactofAcuteandLateStentMalappositionafter Primary Intervention in Patients with Acute MyocardialInfarction:anIntravascularUltrasoundSubstudyoftheHarmonizingOutcomes with Revascularization and Stents in Acute MyocardialInfarction (HORIZONS-AMI) trial, Circulation, Vol.122, pp.1077-84.2010.
  • DaemenJ,WenaweserP,TsuchidaK,AbrechtL,VainaS,MorgerC,etal.,Early and Late Coronary Stent Thrombosis of Sirolimus-Elutingand Paclitaxel-Eluting Stents in Routine Clinical Practice: Datafrom a Large Two-Institutional Cohort Study. Lancet, Vol.369,pp.667-78,2007.
  • Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C,Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, HessOM,Boersma E, Meier B, Windecker S, Serruys PW, Early and LateCoronary Stent Thrombosis of Sirolimus-Eluting and Paclitaxel-Eluting Stents in Routine Clinical Practice: Data from a LargeTwo-InstitutionalCohortStudy.Lancet,Vol.369,pp.667-78,2007.
  • CutlipDE,BaimDS,HoKK,PopmaJJ,LanskyAJ,CohenDJ,CarrozzaJP Jr, Chauhan MS, Rodriguez O, Kuntz RE.Stent Thrombosis in theModern era: a pooled analysis of multicenter coronary stentclinicaltrials.Circulation,Vol.103,pp.1967-71,2001.
  • Cutlip DE, Windecker S, Mehran R, et al. Clinical End Points inCoronary Stent Trials: a Case for Standardized Definitions,Circulation,Vol.115,pp.2344?51,2007.
  • Cook S, Wenaweser P, Togni M, Billinger M, Morger C, Seiler C,VogelR,HessOM,MeierB,WindeckerS.IncompleteStentAppositionandLateStentThrombosisfollowingDrug-ElutingStentImplantation,Circulation,Vol.115,pp.2426-34,2007.
  • BrennanJM,CurtisJP,DaiD,FitzgeraldS,KhandelwalAK,SpertusJA,RaoSV,SinghM,ShawRE,HoKK,KroneRJ,WeintraubWS,WeaverWD, Peterson ED; National Cardiovascular Data Registry. EnhancedMortality Risk Prediction With a Focus on High-Risk PercutaneousCoronaryIntervention:ResultsFrom1,208,137ProceduresintheNCDR(National Cardiovascular Data Registry), JACC Cardiovasc IntervVOl.6,No.8,p.790-9,2013.
  • BavryAA,KumbhaniDJ,HeltonTJ,BhattDL.RiskofThrombosiswiththe Use of Sirolimus-Eluting Stents for Percutaneous CoronaryIntervention,AmJCardiol,Vol.95,pp.1469?72,2005.
  • Bavry AA, Kumbhani DJ, Helton TJ, Bhatt DL,What is the Risk ofStent Thrombosis Associated with the Use of Paclitaxel-ElutingStents for Percutaneous Coronary Intervention?, J Am Coll Cardiol,Vol.45,pp.941-46,2005.
  • AiroldiF,ColomboA,MoriciN,LatibA,CosgraveJ,BuellesfeldL,et al., Incidence and Predictors of Drug-Eluting Stent ThrombosisDuring and after Discontinuation of Thienopyridine Treatment,Circulation,Vol.116,pp.745?54,2007.
  • AhnYS,ChoJH,KimDH,HwangYJ,JungHM,ChoiMS,etal.,AFatalCase of Simultaneous, very Late Thrombosis Involving ThreeDrug-Eluting Stents in Three Coronary Arteries, Korean Circ J,Vol.38,pp.564?69,2008.